Analyst Price Targets — SLDB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 27, 2026 11:54 am | — | Cantor Fitzgerald | $26.00 | $9.72 | TheFly | Solid Biosciences price target raised to $26 from $16 at Cantor Fitzgerald |
| August 21, 2026 11:27 am | Danielle Brill | Truist Financial | $20.00 | $9.10 | TheFly | Solid Biosciences assumed with a Buy at Truist |
| May 13, 2026 12:39 pm | — | Wedbush | $16.00 | $7.74 | TheFly | Solid Biosciences price target lowered to $16 from $17 at Wedbush |
| May 13, 2026 10:44 am | Biren Amin | Piper Sandler | $18.00 | $7.72 | TheFly | Solid Biosciences price target raised to $18 from $17 at Piper Sandler |
| December 4, 2025 11:41 am | Gil Blum | Needham | $16.00 | $5.19 | TheFly | Solid Biosciences initiated with a Buy at Needham |
| November 4, 2025 10:08 am | — | Barclays | $9.00 | $5.20 | TheFly | Solid Biosciences price target lowered to $9 from $10 at Barclays |
| July 21, 2025 11:52 am | Charles Duncan | Cantor Fitzgerald | $16.00 | $6.76 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Solid Biosciences (SLDB) |
| June 24, 2024 6:09 am | Joseph Schwartz | Leerink Partners | $12.00 | $6.62 | StreetInsider | Leerink Partners Upgrades Solid Biosciences (SLDB) to Outperform |
| May 31, 2024 5:07 am | Biren Amin | Piper Sandler | $20.00 | $7.64 | TheFly | Solid Biosciences transferred with Overweight rating at Piper Sandler |
| May 16, 2024 5:10 am | Gena Wang | Barclays | $18.00 | $9.69 | TheFly | Solid Biosciences price target lowered to $18 from $21 at Barclays |
Latest News for SLDB
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional…
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLDB.
U.S. House Trading
No House trades found for SLDB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.